Shares of Canadian pharmaceutical company Aquinox Pharmaceuticals Inc. US:AQXP soared more than 2000% on an intraday basis over the last two trading sessions — and investors went insane about it on Twitter.

The rally started after the company released positive mid-stage trial results on Friday for a bladder pain drug referred to by its clinical name, AQX-1125. Shares traded up as much as 280% Monday morning after closing up nearly 500% on Friday.

The stock pulled back in afternoon trade, but still ended up closing 81% higher to $18.88. To give perspective, the stock closed at $1.79 on Thursday and its previous record high was $14, recorded on March 12, 2014.

Aquinox has been moving on extremely high volume. Nearly 18 million shares changed hands on Monday — roughly 90 times the stock’s 30-day average volume before the rally began Friday morning.

It’s not uncommon for trial data — positive or negative — to trigger sharp share-price swings for small-cap pharmaceutical companies. Aquinox shares dropped 67% in one trading session on July 9 after the company announced negative trial results for a drug being studied as a treatment for chronic obstructive pulmonary disease.

But this move is noteworthy, and has been gaining an incredible amount of attention on Twitter TWTR, -0.62% , which has become a key platform for day traders swapping ideas and issuing bragging rights.

For what it’s worth, analysts were bewildered.

“I wish I could have a comment…” Canaccord Genuity analyst Corey Davis said in an email.

Some investors were equally as bewildered:

Day traders were overwhelmingly jubilant, however, sending rapid-fire tweets several times a minute talking about $AQXP, which was a largely-unheard-of NASDAQ stock before Friday:

MarketWatch reached out to Twitter Inc. TWTR, -0.62% requesting analytics for the stock’s mentions on the platform but did not immediately hear back. Aquinox did not immediately respond to MarketWatch for comment.

On Friday, Aquinox CEO David Main said the trial results strengthen Aquinox’s confidence in further developing the drug for patients with bladder pain syndrome, or interstitial cystitis, and set a path for eventual approval. However, the company also reported that it trimmed research and development spending by $1 million in its most recent quarter.

Despite cost cuts, Aquinox reported a quarterly loss of $4.8 million, narrower than a $5.4 million loss in the year-earlier period. Cash, cash equivalent and investments were also down, coming in at $29 million as of June 30, versus $41.1 million on Dec. 31.